Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Crispr Therapeutics AG

CRSP
Current price
37.77 USD -0.01 USD (-0.03%)
Last closed 32.38 USD
ISIN CH0334081137
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 240 560 384 USD
Yield for 12 month -32.14 %
1Y
3Y
5Y
10Y
15Y
CRSP
21.11.2021 - 28.11.2021

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Address: Baarerstrasse 14, Zug, Switzerland, 6300

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

82.38 USD

P/E ratio

Dividend Yield

Current Year

+35 000 000 USD

Last Year

+371 206 000 USD

Current Quarter

+35 000 000 USD

Last Quarter

+602 000 USD

Current Year

+37 314 000 USD

Last Year

+240 956 000 USD

Current Quarter

+35 000 000 USD

Last Quarter

-10 551 000 USD

Key Figures CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -447 307 008 USD
Operating Margin TTM -180.96 %
Price to Earnings
Return On Assets TTM -13.04 %
PEG Ratio -0.21
Return On Equity TTM -19.20 %
Wall Street Target Price 82.38 USD
Revenue TTM 37 314 000 USD
Book Value 22.53 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -82.30 %
Dividend Yield
Gross Profit TTM -393 588 992 USD
Earnings per share -4.34 USD
Diluted Eps TTM -4.34 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CRSP

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 333333:100
Payout Ratio
Last Split Date 19.07.2016

Stock Valuation CRSP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 23.36
Enterprise Value Revenue 45.19
Price Sales TTM 86.85
Enterprise Value EBITDA 14.16
Price Book MRQ 1.69

Financials CRSP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CRSP

For 52 weeks

30.04 USD 67.88 USD
50 Day MA 41.04 USD
Shares Short Prior Month 20 307 836
200 Day MA 46.09 USD
Short Ratio 11.75
Shares Short 20 510 014
Short Percent 27.08 %